Advertisement
UK markets close in 3 hours 31 minutes

  • FTSE 100

    8,093.95
    +53.57 (+0.67%)
     

  • FTSE 250

    19,715.79
    -3.58 (-0.02%)
     

  • AIM

    755.22
    +0.53 (+0.07%)
     

  • GBP/EUR

    1.1671
    +0.0026 (+0.23%)
     

  • GBP/USD

    1.2512
    +0.0050 (+0.40%)
     

  • Bitcoin GBP

    51,034.27
    -2,151.98 (-4.05%)
     

  • CMC Crypto 200

    1,358.01
    -24.56 (-1.78%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.95
    +0.14 (+0.17%)
     

  • GOLD FUTURES

    2,342.00
    +3.60 (+0.15%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,967.42
    -121.28 (-0.67%)
     

  • CAC 40

    8,013.73
    -78.13 (-0.97%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Aerie Pharmaceuticals (AERI): Moving Average Crossover Alert

Zacks Equity Research
Updated
Companies In The News Are: CSCO,DDS,JPM,BRK.B,AMAT

Aerie Pharmaceuticals, Inc. AERI could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for AERI broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

This has already started to take place, as the stock has moved lower by 9.1% in the past four weeks. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for AERI stock.

If that wasn’t enough, Aerie Pharmaceuticals isn’t looking too great from an earnings estimate revision perspective either. It appears as though many analysts have been reducing their earnings expectations for the stock lately, which is usually not a good sign of things to come.

Consider that in the last 30 days, 1 estimate has been reduced, while none has moved higher. Add this into a similar move lower in the consensus estimate, and there is plenty of reason to be bearish here.

ADVERTISEMENT

That is why we currently have a Zacks Rank #4 (Sell) on this stock and are looking for it to underperform in the weeks ahead. So either avoid this stock or consider jumping ship until the estimates and technical factors turn around for AERI. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Aerie Pharmaceuticals, Inc. (AERI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.